REVEL:A pivotal phase III trial in patients with metastatic NSCLC (nonsquamous or squamous histologies) with disease progression on or after platinum-based therapy(N=1253)¹

A large, multinational, randomized, double-blind, placebo-controlled trial in patients with disease progression on or after one platinum-based therapy for locally advanced or metastatic disease

REVEL trial design1,2

ECOG=Eastern Cooperative Oncology Group; PS=performance status; IV=intravenous.
*Stratification factors: Geographic region, ECOG PS, prior maintenance therapy, and gender.
24 patients at East Asian sites received a starting dose of docetaxel at 60 mg/m2 every 3 weeks.

Efficacy Outcome Measure: Overall survival (OS)
Supportive Efficacy Outcome Measures: Progression-free survival (PFS), objective response rate (ORR)

  • Patients received treatment until disease progression, unacceptable toxicity, withdrawal, or death3

© 2015, PeerDirect Publishing
RB95999 © Lilly USA, LLC 2015. All rights reserved.


References:
  1. CYRAMZA (ramucirumab) [package insert]. India, Eli Lilly & Company (India) Pvt. Ltd.
  2. Supplement to: Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-673.
  3. Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-673.
Top